The well-established leader in oncology, Roche has taken an unaccustomed back seat in the emerging field of cancer immunotherapy. But with nine immuno-oncology assets in the clinic and its PD-L1 inhibitor Tecentriq (atezolizumab) clearing FDA a couple weeks before ASCO, the time has come for Roche to make its mark, especially as Tecentriq is the first PD-L1 inhibitor and the first IO therapy for bladder cancer. (Also see "Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market" - Scrip, 19 May, 2016.) Global Head of Cancer Immunotherapy Dan Chen explained Roche's strategy on combinations and how the firm plans to uphold its leadership position.
Q: It's only been a week, but are there early signs of how the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
